Abstract

Prevention of Preterm Delivery with Compounded 17a-Hydroxyprogesterone Caproate

Author(s): Reed-Kane Dana, Kirshbaum Karen

Issue: May/Jun 2006 - Hormone Replacement Therapy

Page(s): 165-171

Download in electronic PDF format for $75
  • Prevention of Preterm Delivery with Compounded 17a-Hydroxyprogesterone Caproate Page 1
  • Prevention of Preterm Delivery with Compounded 17a-Hydroxyprogesterone Caproate Page 2
  • Prevention of Preterm Delivery with Compounded 17a-Hydroxyprogesterone Caproate Page 3
  • Prevention of Preterm Delivery with Compounded 17a-Hydroxyprogesterone Caproate Page 4
  • Prevention of Preterm Delivery with Compounded 17a-Hydroxyprogesterone Caproate Page 5
  • Prevention of Preterm Delivery with Compounded 17a-Hydroxyprogesterone Caproate Page 6
  • Prevention of Preterm Delivery with Compounded 17a-Hydroxyprogesterone Caproate Page 7

Abstract

17a-hydroxyprogesterone caproate is a naturally occurring metabolite of progesterone that is produced in significant quantities during pregnancy. The demand for 17a hydroxyprogesterone caproate, the lack of a commercially available manufactured form approved by the US Food and Drug Administration, and publication of the results of a large trial to determine the effectiveness of the drug in the prevention of preterm delivery have spawned an increased interest in compounded formulations of the drug. The demand also has necessitated a review of the available literature and of past clinical studies, and a look at present and planned studies. Owing to the importance of this drug in pregnancy and the need for safety, accuracy in potency, and sterility in an intramuscular injection (the most common route of administration), compounding pharmacies must be in compliance with the United States Pharmacopeia Chapter <797> standards should they wish to compound this formulation.

Related Keywords

  • women
  • pregnancy
  • preterm labor
  • 17a-hydroxyprogesterone caproate
  • risk factors
  • progesterone
  • preterm delivery

Related Categories

  • LEGAL
  • STERILE PREPARATIONS
  • UNITED STATES PHARMACOPEIA CONVENTIONS
  • DOSAGE FORMS/DRUG CARRIERS
  • ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2006
Pg. 165-171
Prevention of Preterm Delivery with Compounded 17a-Hydroxyprogesterone Caproate
Author(s): Reed-Kane Dana, Kirshbaum Karen
May/Jun 2006
Pg. 172
Case Report: Hydroxyprogesterone Caproate Injection for Prevention of Preterm Labor
Author(s): Fields Shannon W
Nov/Dec 2011
Pg. 446-448
A Retrospective Observational Case Series Analysis of the Usage of Hydroxyprogesterone Caproate for the Prevention of Preterm Labor in Alabama Patients
Author(s): Nolan Sara M, Burgess Christopher A
Jul/Aug 2003
Pg. 299
Hydroxyprogesterone Caproate 250-mg/mL-in-Oil Injection
Author(s): Allen Loyd V Jr
Jan/Feb 2012
Pg. 86-87
PostScription: Best Practice Recommendations for Compounding 17-Hydroxyprogesterone
Author(s): Cabaleiro Joe
Jan/Feb 2013
Pg. 74-85
View Sample
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Author(s): Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K
Sep/Oct 2003
Pg. 330-338
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2
Author(s): Gillson George R, Zava David T
Jul/Aug 2008
Pg. 295-304
Transdermal Progesterone: Effects on Menopausal Symptoms and on Thrombotic, Anticoagulant, and Inflammatory Factors in Postmenopausal Women
Author(s): Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K, Pinson Barbara, Price Carol
Jan/Feb 2004
Pg. 10-14
Women's Oral Health: Is There a Hormonal Link?
Author(s): Preckshot John
Jan/Feb 2004
Pg. 16-21
Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 1
Author(s): Cutter Christopher B
Mar/Apr 2018
Pg. 108-121
Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management
Author(s): Soni Abhishek, Gowthamarajan Kuppusamy, Radhakrishnan Arun
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Jan/Feb 2019
Pg. 62-64
Chemical Stability of Progesterone in Compounded Oral Rapid-dissolving Tablets
Author(s): Sayre Casey L, Cox Christopher, Velazquez Gabriel, Le Minh Thi, Nguyen Amy Hong, Ramos Marjorie, Burrows Anna, Yellepeddi Venkata Kashyap
Nov/Dec 2022
Pg. 446-466
Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Author(s): Allen Loyd V Jr
Jan/Feb 2019
Pg. 14-21
The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 2
Author(s): Williams LaVonn A
Mar/Apr 2004
Pg. 96-99
Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 2
Author(s): Cutter Christopher B
Jul/Aug 2018
Pg. 284-287
The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 1
Author(s): Williams LaVonn
Nov/Dec 2017
Pg. 530-535
Effect of Penetration Enhancers on the Percuaneous Delivery of Hormone Replacement Actives
Author(s): Trimble John O, Light Bob
Nov/Dec 2015
Pg. 491-500
Basics of Sterile Compounding: Sterile Product Packaging and Delivery Systems
Author(s): Akers Michael J
Jan/Feb 2023
Pg. 30-37
Advanced Compounding: Compounding with Microneedle Arrays, Part 3: Microneedle Array Development in the Literature and Quality Control of Microneedle Arrays
Author(s): Allen Loyd V Jr